Stock Analysis

Nyxoah Third Quarter 2024 Earnings: €0.50 loss per share (vs €0.27 loss in 3Q 2023)

ENXTBR:NYXH
Source: Shutterstock

Nyxoah (EBR:NYXH) Third Quarter 2024 Results

Key Financial Results

  • Net loss: €17.1m (loss widened by 124% from 3Q 2023).
  • €0.50 loss per share (further deteriorated from €0.27 loss in 3Q 2023).
earnings-and-revenue-growth
ENXTBR:NYXH Earnings and Revenue Growth November 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nyxoah Earnings Insights

Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Belgium.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You still need to take note of risks, for example - Nyxoah has 4 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Nyxoah might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.